Nature

Graft-versus-host disease articles from across Nature Portfolio

Graft-versus-host disease is a potentially serious complication in a recipient of an allograft (usually a haematopoietic stem cell transplant) that arises from the attack of recipient tissues (such as the skin, liver or gut) by donor-derived T cells.

Latest Research and Reviews

Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- Arnon Nagler
- Myriam Labopin
- Mohamad Mohty
Research13 Apr 2024 Bone Marrow Transplantation
P: 1-10
Post-transplant cyclophosphamide at 80 mg/kg with low dose post-engraftment anti-thymocyte globulin in haploidentical transplantation with myeloablative conditioning
- Lining Wang
- Guilin Xu
- Jiong Hu
Research10 Apr 2024 Bone Marrow Transplantation
P: 1-6
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients
- Xiaoyu Zhang
- Xiaoli Zhao
- Mingzhe Han
ResearchOpen Access05 Apr 2024 Bone Marrow Transplantation
P: 1-9
Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication

Infusion of virus-specific T (VST) cells is used for treating drug-resistant viremia. Here the authors report, as part of the clinical trial, NCT03475212, a lethal case of unexpected bone marrow graft loss and chimerism reversal that is induced by the infusion of third-party VST intended to treat transplantation-related cytomegalovirus viremia.
- Michael D. Keller
- Stefan A. Schattgen
- Catherine M. Bollard
ResearchOpen Access29 Mar 2024 Nature Communications
Volume: 15, P: 2749
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
- Olaf Penack
- Mouad Abouqateb
- Zinaida Peric
ResearchOpen Access15 Mar 2024 Blood Cancer Journal
Volume: 14, P: 45
Thrombin receptor activating peptide-6 decreases acute graft-versus-host disease through activating GPR15
- Cong Liu
- Qiu Lan
- Bin Pan
Research08 Mar 2024 Leukemia
P: 1-13

All Research & Reviews

News and Comment

Insulin eye drops for severe refractory chronic ocular graft-versus-host disease
- V. Tahmaz
- L. Menghesha
- P. Steven
CorrespondenceOpen Access10 Apr 2024 Bone Marrow Transplantation
P: 1-3
GVHD like skin eruption post-autologous stem cell transplantation
- Johnathan Fraebel
- Silvia Park
- Tae Kon Kim
Correspondence11 Mar 2024 Bone Marrow Transplantation
P: 1-4
Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD
- Zahra Hudda
- Amanda Flannery
- Pooja Khandelwal
Correspondence05 Jan 2024 Bone Marrow Transplantation
Volume: 59, P: 425-427
Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease
- Iskra Pusic
- Catherine Lee
- John F. DiPersio
Correspondence09 Dec 2023 Bone Marrow Transplantation
Volume: 59, P: 282-284
Graft-versus-host disease-free, relapse-free, second transplant-free survival in allogeneic hematopoietic cell transplantation for genetic disorders
- Koji Kawaguchi
- Katsutsugu Umeda
- Kohsuke Imai
Correspondence16 Feb 2023 Bone Marrow Transplantation
Volume: 58, P: 600-602
The macrophage activation marker sCD163 in acute and chronic graft-versus-host disease after pediatric hematopoietic stem cell transplantation
- Laura Louise Fosgrau Hergel
- Katrine Kielsen
- Klaus Müller
Correspondence31 Jan 2023 Bone Marrow Transplantation
Volume: 58, P: 587-589

All News & Comment

Search

Advanced search

Quick links